title: Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.
abstract: OBJECTIVE
  Regadenoson was approved for clinical use in Europe in 2011. Since then, it has become the default form of stress at our institution. We have assessed the side-effect profile and tolerability of regadenoson in patients undergoing clinically indicated myocardial perfusion scintigraphy between July 2011 and July 2012.
  
  
  METHODS
  Clinical, stress and imaging data were recorded prospectively. Symptoms during stress were recorded and defined as mild, moderate or severe. An adverse event was defined as any symptom that persisted for more than 30 min or that required investigation or treatment.
  
  
  RESULTS
  Of 1,764 consecutive patients, 1,581 (90%) received regadenoson combined with submaximal exercise unless contraindicated. Symptoms were common (63%) but transient and well-tolerated. The severity of symptoms was recorded in most patients as mild (84%). Dyspnoea (36%) and chest discomfort (12%) were the commonest side effects. Adverse events were reported in eight patients (0.5%), thought to be vasovagal in seven of these. All patients recovered fully without sequelae. There were no deaths, myocardial infarction or hospital admissions. Regadenoson stress was performed in 206 patients (12%) with asthma or chronic obstructive pulmonary disease (COPD) without bronchospasm or any other major side effect.
  
  
  CONCLUSIONS
  We studied the symptom profile of regadenoson in the largest European cohort to date. Regadenoson combined with submaximal exercise was well tolerated, notably also in patients with asthma or COPD. The majority of regadenoson-related adverse events were vasovagal episodes without sequelae.
authors.affiliation: Royal Brompton Hospital, Sydney St, London, SW3 6NP, UK.
authors.forename: M
authors.initials: M
authors.lastname: Brinkert
authors.forename: E
authors.initials: E
authors.lastname: Reyes
authors.forename: S
authors.initials: S
authors.lastname: Walker
authors.forename: K
authors.initials: K
authors.lastname: Latus
authors.forename: A
authors.initials: A
authors.lastname: Maenhout
authors.forename: R
authors.initials: R
authors.lastname: Mizumoto
authors.forename: C
authors.initials: C
authors.lastname: Nkomo
authors.forename: K
authors.initials: K
authors.lastname: Standbridge
authors.forename: K
authors.initials: K
authors.lastname: Wechalekar
authors.forename: S R
authors.initials: SR
authors.lastname: Underwood
mesh_terms: D000368:Aged; D005060:Europe; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055414:Myocardial Perfusion Imaging; D011446:Prospective Studies; D011687:Purines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D019275:Radiopharmaceuticals / Q000009:adverse effects*
chemical_list: D011687:Purines; D011720:Pyrazoles; D019275:Radiopharmaceuticals; C430916:regadenoson